Notícias

ABIFINA marca presença na Semana da OCDE e Indústria – Missão Virtual realizada
pela CNI para promover o encontro...

Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and...

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has quickly spread around the globe. At...

The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India1,2,3,4,5. Since then, it has become dominant in some regions...

The genetic make-up of an individual contributes to the susceptibility and response to viral infection. Although environmental, clinical and social...

Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently...

Vaccine-induced immune thrombotic thrombocytopaenia (VITT) is a rare adverse effect of COVID-19 adenoviral vector vaccines1,2,3. VITT resembles heparin-induced thrombocytopaenia (HIT)...

A ABIFINA elaborou estudo com 50 medicamentos que estarão em domínio público
após a recente decisão do Supremo Tribunal...

The novel coronavirus SARS-CoV-2, responsible for the present COVID-19 global pandemic, is known to bind to the angiotensin converting enzyme-2...

To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal...

COVID-19 is one of the members of the coronavirus family that can easily assail humans. As of now, 10 million...

Clinical biomarkers that accurately predict mortality are needed for the effective management of patients with severe coronavirus disease 2019 (COVID-19)...